Mark Yarmarkovich, PhD

Assistant Professor, Department of Pathology at NYU Langone Health

Speaker

Dr. Mark Yarmarkovich is an Assistant Professor at NYU Grossman School of Medicine focused on developing safe and effective cancer immunotherapies through innovations in biotechnology. He has worked in industry at Genentech and completed his PhD at the University of Pennsylvania and postdoctoral work at the Children's Hospital of Philadelphia, working across a number of disciplines including oncology, protein chemistry, immunology, and computational biology. He applies these experiences to addressing the major challenges in developing the next generation of immunotherapies, leading the development of new technologies for the discovery of tumor-specific targets and the engineering of target-specific receptors. He has discovered novel immunotherapy targets derived from previously undruggable oncoproteins and engineered CAR T cells capable of specifically killing tumor cells. He led the discovery of cross-HLA recognition of Peptide-Centric (PC)-CAR T cells, allowing for significantly expanded application of immunotherapies. Collectively, the application of his efforts has resulted in a PC-CAR T cells entering first-in-class clinical trial in pediatric neuroblastoma in 2024 and a pipeline of PC-CARs being additional cancers. His lab is focused on developing the next generation of immunotherapies to help cancer patients in need.